-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IWHjbRW9nqoZCkakFudMjx8eyhQHBXUZARHTVfDgq48BgY+XmiatFrzQICrCJ7Bx
 bBowLOLelrK2DlNUzJxKrQ==

<SEC-DOCUMENT>0000950144-04-012471.txt : 20041230
<SEC-HEADER>0000950144-04-012471.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041230080759
ACCESSION NUMBER:		0000950144-04-012471
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041229
ITEM INFORMATION:		Entry into a Material Definitive Agreement
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GTX INC /DE/
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		041232447

	BUSINESS ADDRESS:	
		STREET 1:		3 NORTH DUNLAP AVE 3RD FL
		STREET 2:		VAN VLEET BUILDING
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38163
		BUSINESS PHONE:		901-523-9700

	MAIL ADDRESS:	
		STREET 1:		3 N DUNLAP 3RD FLOOR VAN VIEEN BLDG
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38163
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g92560e8vk.htm
<DESCRIPTION>GTX, INC.    8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>GTx, INC.    8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P>
<HR noshade width="26%" align="center" size="1">
<P>



<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>



<P align="center" style="font-size: 10pt"><B>Date of Report (Date of
earliest event reported): </B>December&nbsp;30, 2004 (December&nbsp;29, 2004)


<P align="center" style="font-size: 24pt"><B>GTx, Inc.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of Registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="80%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>005-79588</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>62-1715807</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>3 N. Dunlap Street<BR>
3</B><SUP>rd</SUP> <B>Floor, Van Vleet Building<BR>
Memphis, Tennessee 38163<BR>
(901)&nbsp;523-9700</B><BR>
(Address, including zip code, of Registrant&#146;s principal executive offices<BR>
Registrant&#146;s telephone number, including area code,)



<P align="center" style="font-size: 10pt"><U>_____________________________________________</U><BR>
(Former name or former address, if changed since last report)


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;1.01 Entry into a Material Definitive Agreement.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">SIGNATURE</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;1.01 Entry into a Material Definitive Agreement." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>


<P align="left" style="font-size: 10pt">As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange
Commission on December&nbsp;14, 2004 by GTx, Inc. (the &#147;Company&#148; or &#147;GTx&#148;), on December&nbsp;13, 2004, the
Company entered into a Purchase Agreement with Orion Corporation enabling GTx to purchase all
remaining rights to Toremifene in the United States and additional
rights in all other countries. On December
29, 2004 in connection with the closing of the Purchase Agreement, GTx entered into an Amended and Restated
License and Supply Agreement (&#147;Agreement&#148;) with Orion Corporation (&#147;Orion&#148;) effective January&nbsp;1,
2005. The Agreement amends and restates the Toremifene License and Supply Agreement effective March
30, 2000, which was amended and restated on October&nbsp;22, 2001, and then amended on March&nbsp;5, 2003,
and on December&nbsp;29, 2003. The following summary description of the Agreement does not purport to be
complete, and is qualified in its entirety by reference to the Agreement, which will be filed as an
exhibit to the Company&#146;s Annual Report on Form 10-K for the fiscal year ending December&nbsp;31, 2004.


<P align="left" style="font-size: 10pt">The Agreement governs the parties&#146; rights and obligations with respect to the research,
development, commercialization and manufacture of pharmaceutical products based on the Toremifene
compound. The Agreement grants GTx the exclusive rights and interests to develop and commercialize
Toremifene based products for human use, except products for the prevention and treatment of breast
cancer in countries outside of the United States and the use of Toremifene in the animal health
field worldwide. Orion has agreed to manufacture and supply GTx&#146;s product needs worldwide.


<P align="left" style="font-size: 10pt">Toremifene is the active component in ACAPODENE&#153; (Toremifene Citrate), a product candidate that GTx
is developing in late stage clinical trials for two separate indications in men&#146;s health.
Toremifene has been approved by the FDA for the treatment of metastatic breast cancer and will be
marketed under the name FARESTON&#174; (Toremifene Citrate) by GTx, commencing January&nbsp;1, 2005.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>GTx, Inc.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: December 30, 2004&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Henry P. Doggrell
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Henry P. Doggrell&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">General Counsel/Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
